Received May 15, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (HEPLISAV-B) | DYNAVAX TECHNOLOGIES CORPORATION | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | 2 | 3X937 | — |
Engerix-B Interchangeability with Heplisav; This non-serious case was reported by a nurse via call center representative and described the occurrence of interchange of vaccine products in a 41-year-old male patient who received HBV (Engerix B) (batch number 3X937, expiry date 07-DEC-2025) for prophylaxis. Co-suspect products included Hepatitis b vaccine rHBsAg (yeast) (Heplisav b) for prophylaxis. On 05-MAY-2025, the patient received the 2nd dose of Engerix B. On 03-APR-2025, the patient received Heplisav b. On 05-MAY-2025, an unknown time after receiving Engerix B, the patient experienced interchange of vaccine products (Verbatim: Engerix-B Interchangeability with Heplisav). The outcome of the interchange of vaccine products was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-MAY-2025 Nurse reported that a patient received Heplisav on April 3rd 2025 and on the day of reporting Engerix B was administered to this patient, which led to interchange of vaccine products. The nurse asked how to proceed with the vaccination in order to complete the Hep B series.